Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Cabazitaxel Versus 177Lu-PSMA-617 in Aggressive mCRPC
NCT06738303Phase 2Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan, cabazitaxel ginsenoside liposome injection and carboplatin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Prostate-Specific Antigen response rate at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetancabazitaxel ginsenoside liposome injectioncarboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06738303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738303.